Table 1.
Emerging targets and therapeutics to reduce ASCVD risk. Used and adapted with permission.36 ASCVD: atherosclerotic cardiovascular disease; GLP-1: glucagon-like peptide 1; LDL-C: low density lipoprotein-cholesterol; SGLT-2: sodium glucose cotransporter-2; siRNA: silencing ribonucleic acid; IL-1β: interleukin-1β.
|
| ||
|---|---|---|
| COMORBIDITY | TARGET | THERAPEUTIC |
|
| ||
| Dyslipidemia | LDL-C, triglycerides, lipoprotein(a) | Bempedoic acid, monoclonal antibodies (alirocumab, evolocumab, evinacumab), siRNA (inclisiran), icosapent ethyl, antisense oligonucleotides (APOCIII-LRx, IONIS-APO(a)-LRx) |
|
| ||
| Inflammation | IL-1β | Canakinumab, colchicine |
|
| ||
| Diabetes | SGLT-2, GLP-1 receptor | Canagliflozin, dapagliflozin, empagliflozin, abiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, tirzepatide |
|
| ||
| Obesity | Appetite, stomach capacity | Orlistat, locaserin, naltrexone-bupropion, phentermine-topiramate, liraglutide, tirzepatide, gastric bypass, sleeve gastrectomy, adjustable gastric band, biliopancreatic diversion with duodenal switch |
|
| ||
| Hypertension | Vasopeptidase, aldosterone synthase, soluble epoxide hydrolase, natriuretic peptide A, vasoactive intestinal peptide receptor 2, catheter-based interventions | Vaccines against angiotensin II and its receptor type I, renal denervation, baroreflex activation therapy |
|
| ||
| Thrombosis | Factor Xa, P2Y12 receptor | Rivaroxaban, ticagrelor |
|
| ||